PreTarg-it®: Unlocking the Full Potential of Radioimmunotherapy
The PreTarg-it® platform combines antibody-mediated tumor targeting with the power of radiotherapy to enable precise cancer treatment while protecting healthy tissue.
How PreTarg-it® Works
PreTarg-it® uses a two-step pretargeting approach that separates tumor targeting from radionuclide delivery.
First, a tumor-targeting bispecific antibody accumulates at the tumor site and clears from circulation.
A radioligand is then administered, binding to the tumor-bound antibody to deliver targeted radiation.
This sequential approach is designed to enable more controlled radiation delivery and greater therapeutic precision.
How PreTarg-it® Works
PreTarg-it® uses a two-step pretargeting approach that separates tumor targeting from radionuclide delivery.
First, a tumor-targeting bispecific antibody accumulates at the tumor site and clears from circulation.
A radioligand is then administered, binding to the tumor-bound antibody to deliver targeted radiation.
This sequential approach is designed to enable more controlled radiation delivery and greater therapeutic precision.
Modular Platform Design
PreTarg-it® is a modular platform designed for flexible development across oncology targets and both therapeutic and diagnostic radionuclides. Our platform combines:
Bispecific Antibody
Optimized fully human IgG targeting customer-defined antigens, designed for low immunogenicity and a pretargeting-tailored half-life, eliminating the need for clearing agents. Produced using standard manufacturing processes with high stability.
Radioligand
Clinically validated radioligand with a favorable safety profile, offering high modularity and compatibility with therapeutic and diagnostic radionuclides, manufactured through efficient, scalable processes ensuring consistent product quality.
Bispecific Antibody
Optimized fully human IgG targeting customer-defined antigens, designed for low immunogenicity and a pretargeting-tailored half-life, eliminating the need for clearing agents. Produced using standard manufacturing processes with high stability.
Radioligand
Clinically validated radioligand with a favorable safety profile, offering high modularity and compatibility with therapeutic and diagnostic radionuclides, manufactured through efficient, scalable processes ensuring consistent product quality.
Designed for Next Generation Radiopharmaceutical Therapy
Designed for Next Generation Radiopharmaceutical Therapy
Modular Platform Design
Adaptable coupling of tumor targets with radioligands.
Modular Platform Design
Adaptable coupling of tumor targets with radioligands.
The PreTarg-it® Pipeline
Our PreTarg-it® platform supports a growing pipeline of pretargeted radioimmunotherapy programs addressing multiple solid tumor indications.
The modular platform design enables rapid expansion to additional targets while maintaining a consistent development framework.
